Immunoconjugates

Patent metadata

Field	Value
Publication number	US-10316104-B2
Application number	US-201614996893-A
Country	US
Kind code	B2
Filing date	Jan 15, 2016
Priority date	Apr 29, 2011
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

First claim

The invention claimed is:

1. An immunoconjugate comprising a mutant interleukin-2 (IL-2) polypeptide and an antigen binding moiety,
wherein said mutant IL-2 polypeptide is a mutant of a human IL-2 polypeptide comprising the amino acid sequence of SEQ ID NO: 2 and comprises three amino acid substitutions at positions corresponding to positions 42, 45, and 72 of SEQ ID NO: 2, wherein said three amino acid substitutions are F42A, Y45A and L72G; and
wherein said antigen binding moiety is an IgG1 subclass immunoglobulin molecule specific for Carcinoembryonic Antigen (CEA), comprising
a heavy chain variable region comprising, according to the Kabat numbering system, (i) the heavy chain CDR1, (ii) heavy chain CDR2 and (iii) heavy chain CDR3 of the heavy chain variable region sequence of SEQ ID NO: 191, and
a light chain variable region comprising, according to the Kabat numbering system, (i) the light chain CDR1, (ii) light chain CDR2, and (iii) light chain CDR3 of the light chain variable region of SEQ ID NO: 189.

2. A pharmaceutical composition comprising the immunoconjugate of claim 1 and a pharmaceutically acceptable carrier.

3. The immunoconjugate of claim 1 , wherein said mutant IL-2 polypeptide further comprises one or more of the amino acid substitutions at positions corresponding to positions 3 or 125 of SEQ ID NO: 2, wherein said one or more of the amino acid substitutions are T3A or C125A.

4. The immunoconjugate of claim 1 , wherein said mutant IL-2 polypeptide comprises the sequence of SEQ ID NO: 3.

5. The immunoconjugate of claim 4 , wherein said mutant IL-2 polypeptide is joined at its amino-terminal amino acid to the carboxy-terminal amino acid of one of the immunoglobulin heavy chains.

6. The immunoconjugate of claim 5 , wherein the immunoconjugate comprises not more than one mutant IL-2 polypeptide.

7. The immunoconjugate of claim 6 , wherein the IgG 1 subclass immunoglobulin molecule comprises in the Fc domain a modification promoting heterodimerization of two non-identical immunoglobulin heavy chains.

8. The immunoconjugate of claim 7 , wherein the modification is a knob-into-hole modification, comprising a knob modification in one of the immunoglobulin heavy chains and a hole modification in the other one of the immunoglobulin heavy chains.

9. The immunoconjugate of claim 8 , wherein the knob modification comprises the amino acid substitution T366W in one of the two immunoglobulin heavy chains, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two immunoglobulin heavy chains, according to the EU numbering of Kabat.

10. The immunoconjugate of claim 9 , wherein the immunoglobulin heavy chain comprising the knob modification further comprises the amino acid substitution S354C, and the immunoglobulin heavy chain comprising the hole modification further comprises the amino acid substitution Y349C, according to the EU numbering of Kabat.

11. The immunoconjugate of claim 4 , wherein the IgG 1 molecule comprises in its Fc domain one or more amino acid mutations that reduce the binding affinity of the immunoconjugate to an FcγRIIIa, FcγRI or FcγRIIa receptor.

12. The immunoconjugate of claim 11 , wherein the IgG 1 molecule comprises the amino acid mutations L234A, L235A and P329G, according to the EU numbering of Kabat.

13. The immunoconjugate of claim 4 , wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 191, and the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 189.

14. The immunoconjugate of claim 1 , wherein said mutant IL-2 polypeptide is joined at its amino-terminal amino acid to the carboxy-terminal amino acid of one of the heavy chains of said immunoglobulin molecule.

15. The immunoconjugate of claim 14 , wherein the immunoconjugate comprises not more than one mutant IL-2 polypeptide.

16. The immunoconjugate of claim 1 , wherein the IgG 1 subclass immunoglobulin molecule comprises in the Fc domain a modification promoting heterodimerization of two non-identical immunoglobulin heavy chains.

17. The immunoconjugate of claim 16 , wherein the modification is a knob-into-hole modification, comprising a knob modification in one of the immunoglobulin heavy chains and a hole modification in the other one of the immunoglobulin heavy chains.

18. The immunoconjugate of claim 17 , wherein the knob modification comprises the amino acid substitution T366W in one of the two immunoglobulin heavy chains, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two immunoglobulin heavy chains, according to the EU numbering of Kabat.

19. The immunoconjugate of claim 18 , wherein the immunoglobulin heavy chain comprising the knob modification further comprises the amino acid substitution S354C, and the immunoglobulin heavy chain comprising the hole modification further comprises the amino acid substitution Y349C, according to the EU numbering of Kabat.

20. The immunoconjugate of claim 1 , wherein the IgG 1 molecule comprises in its Fc domain one or more amino acid mutations that reduce the binding affinity of the immunoconjugate to an FcγRIIIa, FcγRI or FcγRIIa receptor.

21. The immunoconjugate of claim 20 , wherein the IgG 1 molecule comprises the amino acid mutations L234A, L235A and P329G, according to the EU numbering of Kabat.

22. The immunoconjugate of claim 1 , wherein the heavy chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 191, and the light chain variable region comprises a sequence that is at least about 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 189.

23. The immunoconjugate of claim 1 , comprising a polypeptide sequence that is at least about 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 277, a polypeptide sequence that is at least about 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 281, and a polypeptide sequence that is at least about 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 283.

Assignees

• Roche Glycart Ag

Inventors

• Ast Oliver
• Bruenker Peter
• Hofer Thomas U
• Hosse Ralf
• Klein Christian
• Moessner Ekkehard
• Umana Pablo

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P17/06

  Antipsoriatics · CPC title